Last reviewed · How we verify
nanoparticulate paclitaxel
At a glance
| Generic name | nanoparticulate paclitaxel |
|---|---|
| Also known as | Nanotax |
| Sponsor | CritiTech, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Expanded Access to NanoPac
- Trial of NanoPac Intratumoral Injection in Lung Cancer (PHASE2)
- Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Trial of NanoPac Focal Therapy for Prostate Cancer (PHASE2)
- Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms (PHASE2)
- Study of SOR007 Ointment for Actinic Keratosis (PHASE2)
- Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) (PHASE2)
- Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nanoparticulate paclitaxel CI brief — competitive landscape report
- nanoparticulate paclitaxel updates RSS · CI watch RSS
- CritiTech, Inc. portfolio CI